While anti-PD-1 immunotherapy has gained the spotlight due to its prominence in the literature, the neutralization of other inhibitory receptors such as LAG3 and CTLA4 has been proposed for monotherapy and combinatorial therapy in different clinical trial settings to fine-tune cancer immunotherapy. The gene discussed is PDCD1; the disease is cancer.